Phipps AI, Newcomb PA, Garcia-Albeniz X, Hutter CM, White E, Fuchs CS, Hazra A, Ogino S, Nan H, Ma J, Campbell PT, Figueiredo JC, Peters U, Chan AT. Association between colorectal cancer susceptibility loci and survival time after diagnosis with colorectal cancer. Gastroenterology. 2012 Jul;143(1):51-4. doi: 10.1053/j.gastro.2012.04.052
Spiegel B, Camilleri M, Bolus R, Andresen V, Chey WD, Fehnel S, Mangel A, Talley NJ, Whitehead WE. Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome foundation report. Gastroenterology. 2009 Dec 1;137(6):1944-53.
Johnson FR, Ozdemir F, Mansfield CA, Hass S, Miller DP, Siegel CA, Sands BE. Crohn's disease patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007 Sep;133(3):769-79.
Northcutt AR, Camilleri M, Mayer EA, Dossman DA, Dukes GE, Ehsanullah RSB, McSorley DJ. Alosetron, a 5-HT3-receptor antagonist, is effective in the treatment of female irritable bowel syndrome patients. Gastroenterology. 1998;114:A812.
Vakil N, McSorley DJ. The incremental cost and utility of cultures for helicobacter pylori. Gastroenterology. 1997;112(4):A319.
Ciociola AA, Koch KM, McSorley DJ. Safety and pharmacokinetics of chronic oral dosing of gr122311x (ranitidine bismuth citrate), a new bismuth compound with anti-secretory activity. Gastroenterology. 1992;102(4):A50.
Ciociola AA, Koch KM, McSorley DJ. Safety and pharmacokinetics of ascending oral doses of gr122311x (ranitidine bismuth citrate), a new bismuth compound with anti-secretory properties. Gastroenterology. 1992;102(4):A51.